Crossmark

Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis

Crossref DOI link: https://doi.org/10.1186/s40360-025-00885-4

Published Online: 2025-05-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Min

Li, Qianqian

Fang, Min

Zhang, Hong

Ding, Yanhua
License Information

Text and Data Mining valid from 2025-05-19

Version of Record valid from 2025-05-19
More Information

Article History

Received: 3 January 2025

Accepted: 28 February 2025

First Online: 19 May 2025

Declarations

:

: The study was approved by Ethics Committee of the First Hospital of Jilin University (approval number: 20Y116-001) and conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice. Written informed consent was obtained from each participant before the study commenced.

: All participants provided written informed consent for this study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below